PortalPublikationenSARS-CoV-2-antibody response in health care workers after va...

SARS-CoV-2-antibody response in health care workers after vaccination or natural infection in a longitudinal observational study

Standard

SARS-CoV-2-antibody response in health care workers after vaccination or natural infection in a longitudinal observational study. / Herzberg, Jonas; Vollmer, Tanja; Fischer, Bastian; Becher, Heiko; Becker, Ann-Kristin; Honarpisheh, Human; Guraya, Salman Yousuf; Strate, Tim; Knabbe, Cornelius.

in: VACCINE, Jahrgang 40, Nr. 2, 21.01.2022, S. 206-212.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Herzberg, J, Vollmer, T, Fischer, B, Becher, H, Becker, A-K, Honarpisheh, H, Guraya, SY, Strate, T & Knabbe, C 2022, 'SARS-CoV-2-antibody response in health care workers after vaccination or natural infection in a longitudinal observational study', VACCINE, Jg. 40, Nr. 2, S. 206-212. https://doi.org/10.1016/j.vaccine.2021.11.081

APA

Herzberg, J., Vollmer, T., Fischer, B., Becher, H., Becker, A-K., Honarpisheh, H., Guraya, S. Y., Strate, T., & Knabbe, C. (2022). SARS-CoV-2-antibody response in health care workers after vaccination or natural infection in a longitudinal observational study. VACCINE, 40(2), 206-212. https://doi.org/10.1016/j.vaccine.2021.11.081

Vancouver

Herzberg J, Vollmer T, Fischer B, Becher H, Becker A-K, Honarpisheh H et al. SARS-CoV-2-antibody response in health care workers after vaccination or natural infection in a longitudinal observational study. VACCINE. 2022 Jan 21;40(2):206-212. https://doi.org/10.1016/j.vaccine.2021.11.081

Bibtex

@article{7ee95dca73444b12b1b469cd7ae2570a,
title = "SARS-CoV-2-antibody response in health care workers after vaccination or natural infection in a longitudinal observational study",
abstract = "BACKGROUND: Following a year of development, several vaccines have been approved to contain the global COVID-19 pandemic. Real world comparative data on immune response following vaccination or natural infection are rare.METHODS: We conducted a longitudinal observational study in employees at a secondary care hospital affected by the COVID-19 pandemic. Comparisons were made about the presence of anti-SARS-CoV-2 immunglobulin G (IgG) antibody ratio after natural infection, or vaccination with one or two doses of BioNTech/Pfizer (BNT162b2), or one dose of AstraZenca (Vaxzevria) vaccine.RESULTS: We found a 100% humoral response rate in participants after 2 doses of BNT162b2 vaccine. The antibody ratio in participants with one dose BNT162b2 and Vaxzevria did not differ significantly to those with previous PCR-confirmed infection, whereas this was significantly lower in comparison to two doses of BioNTech/Pfizer. We could not identify a correlation with previous comorbidities, obesity or age within this study. Smoking showed a negative effect on the antibody response (p = 0.006) CONCLUSION: Our data provide an overview about humoral immune response after natural SARS-CoV-2 infection or following vaccination, and supports the usage of booster vaccinations, especially in patients after a natural SARS-CoV-2 infection.",
keywords = "Antibody Formation, BNT162 Vaccine, COVID-19, COVID-19 Vaccines, Health Personnel, Humans, Pandemics, SARS-CoV-2, Vaccination",
author = "Jonas Herzberg and Tanja Vollmer and Bastian Fischer and Heiko Becher and Ann-Kristin Becker and Human Honarpisheh and Guraya, {Salman Yousuf} and Tim Strate and Cornelius Knabbe",
note = "Copyright {\textcopyright} 2021 Elsevier Ltd. All rights reserved.",
year = "2022",
month = jan,
day = "21",
doi = "10.1016/j.vaccine.2021.11.081",
language = "English",
volume = "40",
pages = "206--212",
journal = "VACCINE",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "2",

}

RIS

TY - JOUR

T1 - SARS-CoV-2-antibody response in health care workers after vaccination or natural infection in a longitudinal observational study

AU - Herzberg, Jonas

AU - Vollmer, Tanja

AU - Fischer, Bastian

AU - Becher, Heiko

AU - Becker, Ann-Kristin

AU - Honarpisheh, Human

AU - Guraya, Salman Yousuf

AU - Strate, Tim

AU - Knabbe, Cornelius

N1 - Copyright © 2021 Elsevier Ltd. All rights reserved.

PY - 2022/1/21

Y1 - 2022/1/21

N2 - BACKGROUND: Following a year of development, several vaccines have been approved to contain the global COVID-19 pandemic. Real world comparative data on immune response following vaccination or natural infection are rare.METHODS: We conducted a longitudinal observational study in employees at a secondary care hospital affected by the COVID-19 pandemic. Comparisons were made about the presence of anti-SARS-CoV-2 immunglobulin G (IgG) antibody ratio after natural infection, or vaccination with one or two doses of BioNTech/Pfizer (BNT162b2), or one dose of AstraZenca (Vaxzevria) vaccine.RESULTS: We found a 100% humoral response rate in participants after 2 doses of BNT162b2 vaccine. The antibody ratio in participants with one dose BNT162b2 and Vaxzevria did not differ significantly to those with previous PCR-confirmed infection, whereas this was significantly lower in comparison to two doses of BioNTech/Pfizer. We could not identify a correlation with previous comorbidities, obesity or age within this study. Smoking showed a negative effect on the antibody response (p = 0.006) CONCLUSION: Our data provide an overview about humoral immune response after natural SARS-CoV-2 infection or following vaccination, and supports the usage of booster vaccinations, especially in patients after a natural SARS-CoV-2 infection.

AB - BACKGROUND: Following a year of development, several vaccines have been approved to contain the global COVID-19 pandemic. Real world comparative data on immune response following vaccination or natural infection are rare.METHODS: We conducted a longitudinal observational study in employees at a secondary care hospital affected by the COVID-19 pandemic. Comparisons were made about the presence of anti-SARS-CoV-2 immunglobulin G (IgG) antibody ratio after natural infection, or vaccination with one or two doses of BioNTech/Pfizer (BNT162b2), or one dose of AstraZenca (Vaxzevria) vaccine.RESULTS: We found a 100% humoral response rate in participants after 2 doses of BNT162b2 vaccine. The antibody ratio in participants with one dose BNT162b2 and Vaxzevria did not differ significantly to those with previous PCR-confirmed infection, whereas this was significantly lower in comparison to two doses of BioNTech/Pfizer. We could not identify a correlation with previous comorbidities, obesity or age within this study. Smoking showed a negative effect on the antibody response (p = 0.006) CONCLUSION: Our data provide an overview about humoral immune response after natural SARS-CoV-2 infection or following vaccination, and supports the usage of booster vaccinations, especially in patients after a natural SARS-CoV-2 infection.

KW - Antibody Formation

KW - BNT162 Vaccine

KW - COVID-19

KW - COVID-19 Vaccines

KW - Health Personnel

KW - Humans

KW - Pandemics

KW - SARS-CoV-2

KW - Vaccination

U2 - 10.1016/j.vaccine.2021.11.081

DO - 10.1016/j.vaccine.2021.11.081

M3 - SCORING: Journal article

C2 - 34895938

VL - 40

SP - 206

EP - 212

JO - VACCINE

JF - VACCINE

SN - 0264-410X

IS - 2

ER -